medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number S1

<< Back Next >>

Ann Hepatol 2006; 5 (S1)

Module X
Treatment of hepatitis C patients who do not respond to treatment or relapse after treatment

Dehesa VM

Language: English
References: 13
Page: 40-41
PDF size: 37.98 Kb.


Text Extraction

Responses to therapy with pegylated interferon plus ribavirin vary according to the hepatitis C virus (HCV) genotype present. Patients with HCV genotype 1a have a sustained response rate of 42%–52%, and patients with genotypes 2 and 3 have a sustained response rate of 76%–84%. If viral load is not reduced by 2 log10 by week 12 of treatment, the patient is considered a nonresponder. If the virus is undetectable at the termination of treatment (week 24 for genotypes other than type 1 and week 48 for genotype 1) but reappears 6 months to a year after treatment, the patient is deemed to have relapsed.


REFERENCES

  1. Fried MW, Shiffman MI., Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  2. Manns MP, McHutchinson JG, Gordon SC, et al Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

  3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-55.

  4. Pawlotsky JM, Mechanism of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003; 59: 1-11.

  5. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499.

  6. Schiffman MI. Management of interferon therapy nonresponders. Clin Liver Dis 2001; 5: 1025-1043.

  7. Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy a meta-analysis of individual patient data. Gut 2002; 51: 864-9.

  8. Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Sem Liv Dis 2003; 23(Suppl.1): 47-52.

  9. Kalmowitz BD, Afdhal NH. Terapias de mantenimiento en la hepatitis C. Curr Hepatitis Reports 2004; 1: 29-36.

  10. Kleiner DE. The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. Sem Liv Dis 2005; 25: 52-64.

  11. Pockros PJ. Current treatments inmunomoduladores en la infection por HCV. Current Hepatitis Reports 2004; 1: 37-44.

  12. Juárez JA, Méndez J, Chirino R, Dehesa M. Terapia triple con pegylated interferon α2a, ribavirin y amantadita en el treatment de la hepatitis crónica C en patients no respondedores o con recaída a pegylated interferon a2a y ribavirin. Ann Hepatology 2006 en prensa.

  13. Berg T, Von Wagner M, Heintges T, et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa 2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology 2004; 40(Suppl.1): 238A. Abstract #169.




2020     |     www.medigraphic.com